Biogen(BIIB) - 2025 Q3 - Quarterly Results

FORM 8-K Filing Information Details Biogen Inc.'s registrant information, common stock registration, and the report's filing date Registrant Information This section identifies Biogen Inc. as the registrant, detailing its incorporation state, commission file number, IRS employer ID, principal executive offices, and telephone number - Registrant: Biogen Inc., incorporated in Delaware[2] - Date of Report: October 14, 2025[2] Securities Information The company's common stock is registered on The Nasdaq Global Select Market under the trading symbol BIIB Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.0005 par value | BIIB | The Nasdaq Global Select Market | - Biogen Inc. is not an emerging growth company[4] Item 2.02 Results of Operations and Financial Condition Presents preliminary Q3 2025 financial estimates, R&D expense definitions, and forward-looking statement disclosures Estimated Financial Impact for Q3 2025 Biogen Inc. anticipates an approximate $2 million pre-tax charge for acquired in-process research and development, upfront and milestone expense in Q3 2025, which is expected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.01 Estimated Q3 2025 Financial Impact | Metric | Estimated Impact (USD) | | :------------------------------------------------------------------ | :--------------------- | | Acquired in-process R&D, upfront and milestone expense (pre-tax) | ~$2 million | | Impact on GAAP and non-GAAP net income per diluted share | ~($0.01) per share | Definition and Presentation of Acquired In-Process R&D Expense Starting Q1 2025, Biogen began presenting acquired in-process research and development, upfront and milestone expense as a separate line item, which the company does not forecast due to uncertainty - Acquired in-process R&D, upfront, and milestone expense began separate line item presentation in Q1 2025[6] - Expense encompasses costs from collaboration and license agreements, including upfront/milestone payments and premiums on equity securities/asset acquisitions of acquired in-process R&D[6] - Biogen does not forecast these expenses due to their uncertain future occurrence, magnitude, and timing[6] Preliminary Nature of Results The financial results for the quarter ended September 30, 2025, are preliminary and subject to finalization, with no assurance that final results will not differ from these unaudited estimates - Q3 2025 results are preliminary and subject to financial statement closing procedures[7] - Final results may differ from preliminary unaudited estimates[7] Note Regarding Forward-Looking Statements This report contains forward-looking statements, made under the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties, and are not publicly updated - Forward-looking statements are subject to substantial risks and uncertainties, potentially causing actual results to differ materially[8][9] - Statements are based on management's current beliefs, assumptions, and available information[9] - Investors are cautioned against undue reliance; the company does not undertake to publicly update these statements[10] Item 9.01 Financial Statements and Exhibits Lists the exhibits furnished with the Form 8-K, including the interactive data file Exhibits This section lists the exhibits furnished as part of the Current Report on Form 8-K, specifically Exhibit 104, which is the Cover Page Interactive Data File Exhibits Furnished | Exhibit No. | Description | | :---------- | :------------------------------------------------ | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Signatures Confirms the official signing of the report by Biogen Inc.'s Secretary on October 14, 2025 Report Signature The report was duly signed on behalf of Biogen Inc. by Wendell Taylor, Secretary, on October 14, 2025, in accordance with the requirements of the Securities Exchange Act of 1934 - Report signed by Wendell Taylor, Secretary, on behalf of Biogen Inc[15] - Date of signature: October 14, 2025[15]